带有二氢噻吩或四氢噻吩亚基的多环噻吩并二氢吲哚的合成尚未见报道,尽管这些化合物可能具有有趣的药用特性。在此,我们报告了一种通过正式 [2+2+1] 分子内脱芳构化环化炔基吲哚与 K 2 S 和 S 8作为硫化物来源获得多环二氢噻吩的方案。此外,四氢噻吩并二氢吲哚是通过一锅两步法立体选择性合成的,包括 AgNO 3催化的烯基脱芳构化,然后是两个涉及 K 2 S 的亲核加成反应。
Polycyclic indolines and indolenines were synthesized via base-catalyzed intramolecular dearomatizing 3-alkenylation reactions of alkynyl indoles 1 at room temperature. The base enhanced the nucleophilicity of the carbon at the 3-position of the indole moiety, facilitating an exclusive 5-exo-dig cyclization reaction with the alkyne to form spiroindolenines 2. The imine functionality of 2 could undergo
多环的二氢吲哚和假吲哚合成通过在室温下炔基吲哚1的碱催化的分子内dearomatizing 3-烯基化反应。碱增强了吲哚部分 3 位碳的亲核性,促进与炔烃的独家 5- exo- dig 环化反应形成螺吲哚 2。 2 的亚胺官能团可以进行原位亲核加成形成螺吲哚3 当 R 是氨基甲酰基或还原形成螺二氢吲哚时 4 当 R 是 H 时。
Synthesis and reactions of N-indol-3-ylmethylalkylammes and related compounds
作者:El-Sayed M. Afsah、Anthony H. Jackson
DOI:10.1039/p19840001929
日期:——
appropriate primary alkylamine. The use of tryptamine and propane-1,3-diamine in the exchange reaction afforded N-indol-3-ylmethyltryptamine (2), and N,N′-bis(indol-3-ylmethyl)propane-1,3-diamine (3) respectively, whereas the use of methylamine gave N,N-bis(indol-3-ylmethyl)methylamine (4). The exchange reaction has been extended by the use of amino acids to give N,N-bis(indol-3-ylmethyl)tryptophan (6)
The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.
The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.
The invention relates to novel sulfonylamino-acetic acid derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of such compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.